United Therapeutics Corp (UTHR) Reports Q4 EPS of $0.79, Reaffirms FY12, FY13 Guidance
Tweet Send to a FriendGet Alerts UTHR Hot Sheet
Price: $67.61 -0.31%
Revenue Growth %: +19.6%
Financial Fact:
Total operating expenses: 115.21M
Today's EPS Names:
TARO, SENEA, UQM, More
Revenue Growth %: +19.6%
Financial Fact:
Total operating expenses: 115.21M
Today's EPS Names:
TARO, SENEA, UQM, More
Trade UTHR Now!
United Therapeutics Corp (NASDAQ: UTHR) reported Q4 EPS of $0.79, $0.08 worse than the analyst estimate of $0.87. Revenue for the quarter came in at $195.2 million versus the consensus estimate of $204.81 million.
United Therapeutics Corp reaffirmed FY2012 guidance.
For earnings history and earnings-related data on United Therapeutics Corp (UTHR) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
United Therapeutics Corp reaffirmed FY2012 guidance.
For earnings history and earnings-related data on United Therapeutics Corp (UTHR) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- salesforce.com, Inc. (CRM) Reports In-Line Q1 EPS; Issues In-Line Q2, FY14 Outlook
- Nordson Corp (NDSN) Reports In-Line Q2 EPS, Q3 Guidance Falls Short
- Pandora Media (P) Reports In-Line Q1 EPS, Revenue & Guidance Beat
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
